Eleven AZD6244 Discussion Tips

Simultaneous integrated boost planning was performed to deliver radiation dose above 60?Gy to the bulky primary tumor and lymph nodes while administering a more conservative dose of 59.4�C63?Gy to small volume CT or PET positive mediastinal lymph nodes measuring 1?cm on short axis on CT were targeted for treatment. Follow-up Patients were assessed weekly during radiation Telomerase for toxicity, and weight was recorded. Following treatment, patients were reassessed at 1?month. Clinical follow-up, CT, and/or PET were performed at 3- to 4-month intervals for 2?years and at 4- to 6-month intervals thereafter. Patients were censored at last follow-up or death. Date of death MDV3100 cell line was confirmed using the social security death index. Hospitalization was confirmed by reviewing the electronic medical record (EPIC). Toxicity scoring and statistical methods Treatment-related toxicity was scored using the Common Terminology Criteria for Adverse Events version 4.0. Statistical analyses were performed on the entire cohort and for the predetermined subset of patients with stage II�CIII non-small cell lung cancer who were treated with definitive chemoradiation. Hospitalizations following treatment were documented in the EPIC electronic medical record. Differences in toxicity rates were assessed AZD6244 price using a two-sided chi-square test with p values of